World Health Organization– tag –
-
First-of-its-Kind Hydrogen Biosensor Integrated into “Smart Underwear” Continuously Monitors Flatulence, Offers New Metabolic Insights
Bioanalysis Zone UK Overview Scientists have developed a pioneering hydrogen biosensor integrated into "Smart Underwear" capable of continuously monitoring flatulence. This non-invasive device provides novel insights into human metabolis... -
Dexcom Secures FDA Authorization for Stelo Glucose Biosensor System, First OTC CGM for Non-Diabetic and Non-Insulin Using Individuals
Devices@FDA (Dexcom) USA Overview Dexcom, Inc. has received FDA authorization for its 'Stelo Glucose Biosensor System,' marking it as the first over-the-counter (OTC) integrated continuous glucose monitor (iCGM) specifically for individu... -
HealthPartners Launches Program Expanding CGM Access and Integrating Pharmacist Support for Insulin-Treated Diabetics
Morningstar (HealthPartners) USA Overview HealthPartners has initiated a new quality improvement program aimed at expanding access to continuous glucose monitoring (CGM) technology and providing personalized support for diabetic patients... -
Boston University Identifies Cardiovascular Metabolic Risk Patterns in Non-Diabetic Adults via CGM Data
EurekAlert! (Boston University Chobanian & Avedisian School of Medicine) USA Overview Researchers at Boston University have discovered that glucose patterns recorded by continuous glucose monitoring (CGM) devices in non-diabetic adults a... -
FDA Approves Dexcom’s Stelo System as First Over-the-Counter Continuous Glucose Monitor for Children Ages 2-18
RadioWHAT (Facebook) USA Overview The FDA has approved Dexcom's Stelo system as the first over-the-counter (OTC) continuous glucose monitor (CGM) available for children aged 2 to 18 without a prescription. This device provides 15-minute ... -
Systematic Review Finds POCT Reduces Emergency Department Treatment Decision Time by 39.5% and Length of Stay by 29.2%
ResearchGate International Overview A systematic review published on ResearchGate on September 9, 2026, reveals that implementing Point-of-Care Testing (POCT) in emergency departments (EDs) significantly reduces laboratory turnaround tim... -
CAR T-Cell Therapy Dramatically Reduces Disease Activity in All 6 Severe Rheumatoid Arthritis Patients in Pivotal Clinical Trial
News-Medical (Nature Medicine paper mentioned) International Overview Groundbreaking clinical trial results reported in Nature Medicine indicate that CAR T-cell therapy successfully treated severe rheumatoid arthritis (RA), with all six ... -
Epocrates Explains: Ketone Tracking Integrated into CGM with First-of-its-Kind Wearable, Enhancing Diabetic Ketoacidosis Prevention
Epocrates USA Overview Epocrates reports that Abbott's Libre Duo 10 Day system is the first wearable device to integrate ketone tracking with continuous glucose monitoring (CGM). This system provides real-time ketone trend data alongside... -
Roche’s Elecsys® pTau217 Blood Test Gains FDA Clearance, Enabling Alzheimer’s Amyloid Pathology Identification in Primary Care for Individuals Aged 55+
Roche (Press Release) USA Overview Roche has announced FDA clearance for its Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, offering a single, blood-based option for clinicians in both primary and specialty care to identify Alz... -
Roche’s PATHWAY® HER2 and VENTANA® HER2 Dual ISH Companion Diagnostics Approved by FDA for ZIIHERA® Eligibility in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
BioSpace USA Overview Roche has received FDA approval for two companion diagnostic tests, PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Cocktail, to identify patients with HER2-positive metastatic gastroesophageal adenocarcino...
